Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B. Garg A, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14. Cancer Chemother Pharmacol. 2014. PMID: 25119184
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF, Cortés J, Brewster M, Visich J, Lum B. Garg A, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2013 Nov;72(5):1133-41. doi: 10.1007/s00280-013-2279-6. Epub 2013 Sep 3. Cancer Chemother Pharmacol. 2013. PMID: 23999693 Free PMC article. Clinical Trial.
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.
Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B. Quartino AL, et al. Among authors: lum b. Cancer Chemother Pharmacol. 2019 Feb;83(2):329-340. doi: 10.1007/s00280-018-3728-z. Epub 2018 Nov 22. Cancer Chemother Pharmacol. 2019. PMID: 30467591 Free PMC article.
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, Li C, Heinzmann D, Jin JY, Lum BL. Quartino AL, et al. Cancer Chemother Pharmacol. 2016 Jan;77(1):77-88. doi: 10.1007/s00280-015-2922-5. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645407 Free PMC article. Clinical Trial.
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Graham RA, et al. Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300760 Free PMC article. Clinical Trial.
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Xu N, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1251-60. doi: 10.1007/s00280-014-2603-9. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344761 Free PMC article. Clinical Trial.
181 results